Press release
Cerbomed GmbH at the 30th International Congress of Clinical Neurophysiology
Please save March 21st and use the chance to get additional information about t-VNS at the Lunch Symposium “Transcutaneous Vagus Nerve Stimulation (t-VNS). Treatment option in epilepsy and pain.” from 12:15 to 13:45 p.m.
About t-VNS
The t-VNS offers a therapy option for patients suffering from epilepsies, depression or pain.
This therapy uses a branch of the vagus nerve that is located closely under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
The t-VNS therapy is carried out autonomously by the patients and is easy to integrate into the daily routine. The advantages of t-VNS: No surgery, no hospitalization, minor side effects.
About cerbomed
Cerbomed GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.
The transcutaneous Vagus Nerve Stimulation received the European clearance (CE mark) for the treatment of epilepsies, depression and pain. Currently two clinical studies are carried out regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.
In September 2012 cerbomed entered into a strategic partnership with Cyberonics, Inc., the global market leader in vagus nerve stimulation.
The therapy device NEMOS is available for treating epilepsies in Germany, Austria, Switzerland and Italy.
Please visit us on www.cerbomed.com.
cerbomed GmbH
Dr. Martin Hyca, Director Marketing
Henkestrasse 91
DE-91052 Erlangen
+49 9131 9202 76 30
martin.hyca@cerbomed.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cerbomed GmbH at the 30th International Congress of Clinical Neurophysiology here
News-ID: 283936 • Views: …
More Releases from cerbomed GmbH
Pharmaceuticals and medical technology will go hand in hand in future – DESITI …
ERLANGEN/HAMBURG, September 17th, 2015 – The medical technology company cerbomed GmbH from Erlangen and the pharmaceutical company DESITIN Arzneimittel GmbH from Hamburg have entered into a groundbreaking distribution agreement: DESITIN has been granted exclusive distribution rights in Germany by cerbomed for the transcutaneous vagus nerve stimulator NEMOS for treatment of epilepsy.
The successful medium-sized independent company DESITIN has been a specialist provider and proficient partner to doctors and patients in the…
transcutaneous Vagus Nerve Stimulation for epilepsies now available in Norway
ERLANGEN/DRAMMEN, May 28th, 2015 – To address the Norwegian market with transcutaneous Vagus Nerve Stimulation (t-VNS), the medical device company cerbomed from Erlangen, Germany, is cooperating with an experienced distribution partner: Scan-Med A/S from Drammen, Norway.
The company, founded in 1982, considers itself as a connecting link between manufacturers of medical devices and hospitals, as well as health institutions and specialized on distribution service and support of medical equipment.
“We are…
Vagus nerve stimulation without surgery now available in Denmark, Finland and Sw …
ERLANGEN/AALBORG, Mai 28th, 2015 – More than 30 percent of all epilepsy patients still suffer from continued occurrence of seizures, despite appropriate treatment with anticonvulsive drugs. For these patients, only few treatment alternatives are available at the moment. One promising therapy option is transcutaneous Vagus Nerve Stimulation (t-VNS), now also available for patients in Denmark, Sweden and Finland. This has been made possible by cerbomed‘s new distributor Cephalon A/S.…
Trial results for transcutaneous Vagus Nerve Stimulation in pharmacoresistant ep …
ERLANGEN/DRESDEN, 30th April 2015 – At the 9th annual joint conference of the three German-speaking regions of the International League Against Epilepsy in Dresden, the results of a trial on transcutaneous Vagus Nerve Stimulation (t-VNS) in pharmacoresistant epilepsy were presented for the first time.
Trial shows reduction in seizures with t-VNS
In the multi-centre, randomised, controlled, 2-arm, double-blind study, 76 adult epilepsy patients from Germany and Austria were treated over 5…
More Releases for Vagus
Vagus Nerve Stimulation Devices Market 2021 | Detailed Report
The Vagus Nerve Stimulation Devices research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information about the…
Vagus Nerve Stimulators Market Size & Growth Analysis Report, 2019-2025
Global vagus nerve stimulator market is expected to grow at a CAGR of 3.5% during the forecast period. Vagus nerve stimulator are those devices that are utilized to stimulate the vagus nerve with electrical impulses. It is used to treat epilepsy and depression. In vagus nerve stimulation, the stimulator is surgically implanted under the skin on the chest, and the device is connected to the left vagus nerve through a…
Vagus Nerve Stimulators Market Scope Assessment 2028
Global Vagus Nerve Stimulators Market: Overview
Increasing number of neurological diseases especially in developing economies is the key factor driving demand in the global vagus nerve stimulators market. Use of vagus nerve stimulation therapy helps in reducing neurological conditions such as neurological tremors and dyskinesia. Its application is also seen in while controlling bladder difficulties, restoration of hand gasp, and improves movement.
Get Sample Copy of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5396
According to the…
Vagus Nerve Stimulators Market Growth, Size & Forecast to 2025
Vagus nerve stimulator market is expected to grow at a CAGR of 3.8% during the forecast period. Vagus nerve stimulator are those devices that are utilized to stimulate the vagus nerve with electrical impulses. It is used to treat epilepsy and depression. In vagus nerve stimulation, the stimulator is surgically implanted under the skin on the chest, and the device is connected to the left vagus nerve through a wire…
Vagus Nerve Stimulation Market Global Industry Analysis Forecast 2023
Healthcare Intelligence Markets announces the addition of a new report on the Global market into its vast depository of research reports. The report is titled “Global Vagal Nerve Stimulators Market Size, Status and Forecast 2023.” Vagus nerve stimulation (VNS) therapy is designed to avoid seizures by sending consistent, mild pulses of electrical signals to the brain through the vagus nerve. These pulses are delivered by a device, which resembles a…
Global Vagus Nerve Stimulation Devices Market Research Report 2017
Global Vagus Nerve Stimulation Devices Industry 2017 Market Overview, Size, Share, Trends, Analysis, Technology, Applications, Growth, Market Status, Demands, Insights, Development, Research and Forecast 2017-2020.
A new research report on the global Vagus Nerve Stimulation Devices market offers a 360-degree overview of it. The report discusses the market in significant details and elucidates all aspects of the global Vagus Nerve Stimulation Devices market likely to impact its growth trajectory in the…
